NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS

Submitted by admin on November 10, 2022 - 10:25am
Source: 
BioSpace
News Tags: 
NRG Therapeutics
funding
Parkinson's Disease
ALS
Headline: 
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS
snippet: 

With a fresh $18 million in the bank, NRG Therapeutics is ready to put its novel mitochondrial approach to the test for two devastating neurodegenerative disorders—Parkinson’s and ALS.

Do Not Allow Advertisers to Use My Personal information